Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Buy Rating for Recursion Pharmaceuticals Amid Strategic Merger and Innovative Drug Development
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns
Recursion Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10